Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TeriGo Study: Once-weekly teriparatide vs continued bisphosphonate in glucocorticoid-induced osteoporosis after bisphosphonate failure
jRCTs031180311Completed
- Sponsor
- Teikyo Academic Research Center
- Start
- Aug 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial of teriparatide in glucocorticoid-induced osteoporosis (GIOP) (2 arms), sponsored by Teikyo Academic Research Center. Primary endpoint: Change in hip and lumbar spine (L1–L4) BMD at week 72. Started Aug 2016; status: completed.
02
Drugs
teriparatide
03
Conditions
glucocorticoid-induced osteoporosis (GIOP)
Beyond the preview
Go deeper on jRCTs031180311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180311.